ArticleCornea2026
Acanthamoeba Keratitis Secondary Glaucoma Associated With Mature Cataract and a Fixed Dilated Pupil in a 40-Eye Series.
Article in Cornea, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dysregulated Intraocular Pressure in Acanthamoeba Keratitis: Clinical Associations, Therapy, and Prognosis.Microorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeThis case series describes the incidence, clinical associations, and treatment outcomes of Acanthamoeba keratitis (AK) secondary glaucoma to identify potential prophylactic measures and optimal treatment.
methodsAK-affected eyes developing secondary glaucoma from 1992 to 2020 were identified from Moorfields databases. The annualized incidence was established from those patients with AK registered between 2000 and 2015.
resultsThe 2000-2015 incidence of AK secondary glaucoma was 26 of 417 (6.2%). Forty eyes (39 patients) developed glaucoma or ocular hypertension; 16 of 28 (57%) had been treated for AK for ≥12 months from onset. Thirty-four of 40 eyes (85%) had an associated keratoplasty; 26 of 40 (65%) had a fixed dilated pupil and/or mature cataract. Sixteen of 40 (40%) underwent antiglaucoma drug treatment alone. Twenty-four of 40 (60%) eyes had surgical treatments including cyclodiode laser (2 eyes) leading to phthisis or evisceration, trabeculectomy (2 eyes) failed, glaucoma drainage devices in 20 of 40 (50%) eyes resulted in glaucoma control in 18/20 (90%) but required additional surgery in 9 of 20 (45%) eyes.
conclusionsMature cataract or a fixed dilated pupil has not been previously identified as a cause of secondary glaucoma in AK. The implications are that both result in angle closure and that early surgery for maturing cataract, despite its complexity, might prevent the development of angle closure. However, the potential for better medical treatment to reduce the time to cure to less than 12 months is likely the most effective way to reduce AK glaucoma incidence. Successful management of AK glaucoma once developed probably requires use of a glaucoma drainage device.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.